Tag : reimbursement

Cardiology

Is mortality readmissions bias a concern for readmission rates under the Hospital Readmissions Reduction Program?

Newsemia
Related Articles Is mortality readmissions bias a concern for readmission rates under the Hospital Readmissions Reduction Program? Health Serv Res. 2020 04;55(2):249-258 Authors: Papanicolas I,...
Latest News

Australia Diabetes Market 2020-2025 by SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, Reimbursement, Company Analysis & Forecast – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Australia Diabetes Market, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, Reimbursement Company Analysis & Forecast” report has been added...
Latest News

Current telehealth reimbursement still a “band-aid”, says Amwell’s CEO

Newsemia
The CEO of the telehealth company that just went public said reimbursement has improved, but not to the point where it is interchangeable with in-person...
Cardiology

Adapting to the Reimbursement Landscape: The Future of Value-Based Care.

Newsemia
Related Articles Adapting to the Reimbursement Landscape: The Future of Value-Based Care. Heart Fail Clin. 2020 Oct;16(4):479-487 Authors: Walradt J, Alphs Jackson H Abstract This...
Latest News

Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients

Newsemia
LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has reached an agreement with the Swiss Federal Office of Public Health (FOPH) and the...
Latest News

Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

Newsemia
BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France Source link...
Latest News

Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)

Newsemia
LONDON–(BUSINESS WIRE)–Vertex announces that the Spanish government has approved national reimbursement of ORKAMBI and SYMKEVI in combination with KALYDECO. Source link...
Latest News

 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

Newsemia
LONDON–(BUSINESS WIRE)–Vertex announced reimbursement of SYMDEKO for eligible patients ages 12 and older, and ORKAMBI for children ages 2 to 5 in Australia. Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy